A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Camrelizumab|DRUG: Apatinib|DRUG: Eribulin
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University